Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development
August 27 2018 - 8:45AM
InvestorsHub NewsWire
501-3292 Production Way, Burnaby, B.C., V5A
4R4
Phone: (604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix Technologies
Provides Technology Update on Marijuana Breathalyzer
Development
The
Cannabix Marijuana Breathalyzer is being developed to give law
enforcement and employers a tool to enforce public
safety.
Vancouver, British
Columbia -- August
27, 2018 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the Cannabix Marijuana Breathalyzer for law
enforcement and the
workplace, is pleased to
report that
characterization
work has demonstrated the
ability to isolate 9-tetrahydrocannabinol
("THC") and suppress
background substrates effectively. Cannabix is
developing an innovative FAIMS (field asymmetric waveform ion
mobility spectrometry) based instrument for the detection of
THC.
Using
the gold standard of mass
spectrometry in tandem with the Cannabix FAIMS prototype
device,
Graph A
and B below show
suppression of
background matrix
allowing
the THC peak to
be
easily
recognized. This demonstrates the
capability of the FAIMS
device to
isolate and detect THC from complex background matrix.
The
characterization work has been
conducted
using a bench version of the
FAIMS device. Cannabix
scientists
have been
actively tuning the FAIMS device
coupled to real
time switchable mass spectrometry to detect key molecules and their
complex pathways in the body to enable the identification of
recency of
use.
The Company also
reports that it has commenced
identification of medical device
manufacturers in order to
implement
human
factor design (single or dual stage
design), verification
testing, and
develop
manufacturing
documentation for standardization
requirements, as well as create multiple devices
for
pilot
testing.
About Cannabix
Technologies Inc.
Cannabix Technologies
Inc. is a leader in marijuana breathalyzer development for law
enforcement and the workplace. Cannabix has established breath
testing technologies in the pursuit of bringing durable, portable
hand-held tools to market to enhance detection of marijuana
impaired driving offences on roads at a time when marijuana is
becoming legal in many global jurisdictions. Cannabix is working to
develop drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in contrast to
urine testing for THC metabolite that requires an invasive
collection and reflects usage, days or even weeks
earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek Safe
Harbor.
On behalf of the
Board of Directors
"Rav
Mlait"
CEO
Cannabix Technologies
Inc.
For further
information, contact the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press
release contains forward-looking information that involves various
risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Apr 2023 to Apr 2024